NACHOLE BROWN: Open Payments
NPI 1801576053 · SEATTLE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,222 in 59 payments from 16 companies in 2025. Trend: 2023 $88 · 2024 $1,540 · 2025 $2,222
Food & beverage: $2,138Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $698 |
| Janssen Biotech, Inc. | 7 | $443 |
| GENZYME CORPORATION | 5 | $244 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $200 |
| PFIZER INC. | 8 | $159 |
| Phathom Pharmaceuticals, Inc. | 2 | $142 |
| Madrigal Pharmaceuticals | 3 | $93 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $73 |
| Ardelyx, Inc. | 2 | $39 |
| Lilly USA, LLC | 1 | $26 |
Products named: TREMFYA, SKYRIZI, DUPIXENT, ENTYVIO, CREON, VOQUEZNA, LINZESS, VELSIPITY.
Industry payments across WA — which companies pay providers there.
